This chapter provides a comprehensive overview of renal and urinary tract conditions with a focus on their implications for life insurance underwriting. It begins with the foundational role of urinalysis, emphasizing its value as a non-invasive, cost-effective screening tool. The discussion includes sample validity, common pitfalls in collection, and interpretation of findings such as hematuria, proteinuria, white blood cells, and urinary casts. A significant portion of the chapter is dedicated to hematuria, detailing its classifications, diagnostic criteria, and risk stratification based on the 2020 American Urological Association (AUA) guidelines. The text outlines the importance of distinguishing between transient and persistent hematuria and highlights malignancy risk factors such as age, gender, smoking history, and occupational exposures. Proteinuria is explored in depth, including its pathophysiology, diagnostic thresholds, and prognostic significance. The chapter explains the utility of protein-to-creatinine and albumin-to-creatinine ratios in assessing renal damage and stratifying mortality risk. It also addresses benign causes such as orthostatic proteinuria and transient elevations due to exercise or dehydration. The evaluation of renal function through serum creatinine, cystatin C, and estimated glomerular filtration rate (eGFR) is discussed, with attention to the limitations of these measures in the insurance setting. The chapter then transitions into specific renal pathologies, including chronic kidney disease (CKD), diabetic nephropathyDiabetic nephropathy, polycystic kidney disease, glomerulonephritis, hypertensive nephropathy, and renal artery stenosis. Each condition is examined in terms of etiology, clinical progression, diagnostic criteria, and implications for underwriting. Acute kidney injury (AKI) and end-stage renal disease (ESRD) are also covered, with emphasis on distinguishing reversible from progressive conditions and assessing long-term prognosis. The chapter concludes with discussions on renal cysts, nephrolithiasis, congenital anomalies, and prostate-specific antigen (PSA) testing, all of which may influence underwriting decisions. Throughout, the chapter integrates clinical guidelines, epidemiological data, and practical considerations to aid medical directors in evaluating renal findings within the context of life insurance risk assessment. The overarching goal is to equip underwriters with the tools to differentiate benign from serious renal conditions and to apply appropriate risk stratification based on current medical evidence.

Evaluation of Kidney and Urinary Tract Conditions

动态工具书词条
发表日期：

2026年

查看全文

Michael Lawrence Moore

摘要

This chapter provides a comprehensive overview of renal and urinary tract conditions with a focus on their implications for life insurance underwriting. It begins with the foundational role of urinalysis, emphasizing its value as a non-invasive, cost-effective screening tool. The discussion includes sample validity, common pitfalls in collection, and interpretation of findings such as hematuria, proteinuria, white blood cells, and urinary casts. A significant portion of the chapter is dedicated to hematuria, detailing its classifications, diagnostic criteria, and risk stratification based on the 2020 American Urological Association (AUA) guidelines. The text outlines the importance of distinguishing between transient and persistent hematuria and highlights malignancy risk factors such as age, gender, smoking history, and occupational exposures. Proteinuria is explored in depth, including its pathophysiology, diagnostic thresholds, and prognostic significance. The chapter explains the utility of protein-to-creatinine and albumin-to-creatinine ratios in assessing renal damage and stratifying mortality risk. It also addresses benign causes such as orthostatic proteinuria and transient elevations due to exercise or dehydration. The evaluation of renal function through serum creatinine, cystatin C, and estimated glomerular filtration rate (eGFR) is discussed, with attention to the limitations of these measures in the insurance setting. The chapter then transitions into specific renal pathologies, including chronic kidney disease (CKD), diabetic nephropathyDiabetic nephropathy, polycystic kidney disease, glomerulonephritis, hypertensive nephropathy, and renal artery stenosis. Each condition is examined in terms of etiology, clinical progression, diagnostic criteria, and implications for underwriting. Acute kidney injury (AKI) and end-stage renal disease (ESRD) are also covered, with emphasis on distinguishing reversible from progressive conditions and assessing long-term prognosis. The chapter concludes with discussions on renal cysts, nephrolithiasis, congenital anomalies, and prostate-specific antigen (PSA) testing, all of which may influence underwriting decisions. Throughout, the chapter integrates clinical guidelines, epidemiological data, and practical considerations to aid medical directors in evaluating renal findings within the context of life insurance risk assessment. The overarching goal is to equip underwriters with the tools to differentiate benign from serious renal conditions and to apply appropriate risk stratification based on current medical evidence.